Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
EditForce and Mitsubishi Tanabe Pharma Enter into License Agreement
Details : In this alliance, MTPC and EditForce aim to create potential novel pharmaceuticals for the specific CNS disease by utilizing the drug R&D. EditForce will proceed with R&D of pharmaceuticals using PPR protein platform technology.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
June 27, 2022